Filing Flows › CG Oncology (CGON) › Q3 2026
CG Oncology (CGON) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 6, 2026
CG Oncology (CGON) reported revenue of $1.6M for the third quarter 2026 (Q3 2026), -4% from a year earlier and +39% from the quarter before.
CG Oncology, Q3 2026: revenue $1.6M (-4% year over year), net loss $56.9M, operating cash flow −$47.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.6M | +39% | -4% |
| Operating profit | −$63.2M | — | — |
| Net earnings | −$56.9M | — | — |
| Operating cash flow | −$47.7M | — | — |
What changed
Revenue was $1.6M in Q3 2026, down 4% year over year and up 39% from the previous quarter.
Operating costs exceeded revenue by $63.2M, an operating margin of -3943.2%. Total costs grew 23% against a revenue fall of 4%. The fastest-growing cost line was Cost of revenue (+69%). The quarter ended with a net loss of $56.9M, narrower than the previous quarter's $79.1M loss.
Operating cash flow was −$47.7M. Non-cash charges added back $1.2M of depreciation and amortization and $8.5M of share-based compensation. Capital expenditures of $1.1M exceeded it, leaving free cash flow of −$48.8M.
Questions
What was CG Oncology's revenue in the third quarter 2026?
CG Oncology (CGON) reported revenue of $1.6M for the third quarter 2026 (Q3 2026), -4% from a year earlier and +39% from the quarter before.
Source: CG Oncology 10-Q on SEC EDGAR.